Company Overview of Biosidus S.A.
Biosidus S.A., a biotechnology company, develops, manufactures, and supplies biosimilars. The company’s product portfolio includes eight therapeutic proteins and retuximab and etanercept product candidates. It offers Epoetin, a synthetic human erythropoietin; Filgrastim, a recombinant methionyl human granulocyte colony stimulating factor; Somatropin, Sinthetic version of human growth hormone; and Lenograstim, Granulocyte colony stimulating factor. Additionally, the company focuses on transgenic animals and gene therapy applied to the management of central and peripheral vascular disease. Biosidus S.A. was founded in 1983 and is based in Buenos Aires, Argentina.
Buenos Aires, C1254ABX
Founded in 1983
54 11 4909 8000
54 11 4909 8055
Key Executives for Biosidus S.A.
Biosidus S.A. does not have any Key Executives recorded.
Similar Private Companies By Industry
|AMEGA Biotech S.A.||Americas|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|NYC2012, Inc.||United States|
|Tax Management Inc||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact Biosidus S.A., please visit www.biosidus.com.ar. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.